Study reveals hidden risks for virus after kidney transplant
NCT ID NCT07621835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 236 kidney transplant patients to find out why some fail to develop immune protection against cytomegalovirus (CMV) in the first 45 days after surgery. Researchers reviewed medical records to compare patients who had a strong immune response with those who did not. The goal is to help doctors predict and manage CMV risk without needing advanced immune tests.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV REACTIVATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
HOSPITAL Universitario REINA SOFIA
Córdoba, 14004, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could the choice of anesthesia quiet the Body's surgical stress response?
- A simple blood test could spot kidney transplant rejection early
- Can your gut bacteria change how transplant drugs work?
- Blood test may take the guesswork out of transplant drug dosing
- Immunotherapy may treat skin cancer in kidney transplant patients without rejection
- Could a daily pill shield transplant patients from a common virus?